Free Trial
NASDAQ:SCLX

Scilex (SCLX) Stock Price, News & Analysis

$0.55 -0.01 (-1.78%)
(As of 11/21/2024 ET)

About Scilex Stock (NASDAQ:SCLX)

Key Stats

Today's Range
$0.55
$0.58
50-Day Range
$0.56
$1.15
52-Week Range
$0.54
$2.63
Volume
1.38 million shs
Average Volume
1.29 million shs
Market Capitalization
$105.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.33
Consensus Rating
Buy

Company Overview

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

Scilex Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
69th Percentile Overall Score

SCLX MarketRank™: 

Scilex scored higher than 69% of companies evaluated by MarketBeat, and ranked 343rd out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Scilex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Scilex has only been the subject of 2 research reports in the past 90 days.

  • Read more about Scilex's stock forecast and price target.
  • Earnings Growth

    Earnings for Scilex are expected to grow in the coming year, from ($0.75) to ($0.39) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Scilex is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Scilex is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    9.50% of the float of Scilex has been sold short.
  • Short Interest Ratio / Days to Cover

    Scilex has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in Scilex has recently decreased by 9.21%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Scilex does not currently pay a dividend.

  • Dividend Growth

    Scilex does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.50% of the float of Scilex has been sold short.
  • Short Interest Ratio / Days to Cover

    Scilex has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in Scilex has recently decreased by 9.21%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Scilex has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.
  • Search Interest

    24 people have searched for SCLX on MarketBeat in the last 30 days. This is an increase of 380% compared to the previous 30 days.
  • MarketBeat Follows

    10 people have added Scilex to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Scilex insiders have bought more of their company's stock than they have sold. Specifically, they have bought $95,234.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 8.73% of the stock of Scilex is held by insiders.

  • Percentage Held by Institutions

    69.67% of the stock of Scilex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Scilex's insider trading history.
Receive SCLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scilex and its competitors with MarketBeat's FREE daily newsletter.

SCLX Stock News Headlines

JD Vance Predicts: Wall Street vs. Trump & Your Money
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Scilex Holding Plans Merger to Boost Semnur Value
Scilex announces successful end of Phase II meeting with FDA
See More Headlines

SCLX Stock Analysis - Frequently Asked Questions

Scilex's stock was trading at $2.04 on January 1st, 2024. Since then, SCLX stock has decreased by 72.5% and is now trading at $0.56.
View the best growth stocks for 2024 here
.

Top institutional investors of Scilex include State Street Corp (3.90%), Janus Henderson Group PLC (0.28%), Donald L. Hagan LLC (0.07%) and XTX Topco Ltd (0.05%). Insiders that own company stock include Henry Ji, Jaisim Shah, Jay Chun, Yue Alexander Wu and Stephen Hoi Ma.
View institutional ownership trends
.

Shares of SCLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Scilex investors own include Rigetti Computing (RGTI), Pfizer (PFE), BioNTech (BNTX), Hertz Global (HTZ), Barrick Gold (GOLD), Nikola (NKLA) and BlackBerry (BB).

Company Calendar

Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SCLX
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.33
High Stock Price Target
$14.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+1,923.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-114,330,000.00
Net Margins
-233.88%
Pretax Margin
-233.86%

Debt

Sales & Book Value

Annual Sales
$46.74 million
Book Value
($1.10) per share

Miscellaneous

Free Float
175,048,000
Market Cap
$107.40 million
Optionable
Optionable
Beta
1.14
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:SCLX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners